• Investment World
• eWorld
• Brand Line
• Mentor
• Life
• Canvas
• Praxis
• Urban Pulse
• Brand Quest
• The New Manager

Stocks

• Quotes
• SE Diary
• Scoreboard
• Open-End Mutual Fund

Cross Currency

• Rates
  
  

Shipping

• Ports
  
  

Archives

• Yesterday
• Datewise
• Resources
• In Focus
• In Depth

Group Sites

• The Hindu
• The Hindu ePaper
• Business Line
• Business Line ePaper
• Sportstar
• Frontline
• The Hindu eBooks
• The Hindu Images

Our Bureau

Hyderabad, March 9

Aurobindo Pharma Ltd has obtained the final approval from the US Food and Drug Administration (USFDA), for its Didanosine Oral Suspension (paediatric powder) in 10 mg/ml dosage. The product is the first general version of the research product, Videx Pediatric power for oral suspension, 10 mg/ml manufactured by Bristol Myers Squibb Pharmaceuticals, according to a company press release here today.

The company manufactures both API and formulation for this generic. Post this development, the total number of Abbreviated New Drug Application (ANDAs) approvals from the USFDA stands at 38, including 22 final and 16 tentative, the release added.

More Stories on : Regulatory Bodies & Rulings | Pharmaceuticals

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
Mahindra launches new Bolero in Gujarat

Copyright © 2007, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line